vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and GERON CORP (GERN). Click either name above to swap in a different company.
GERON CORP is the larger business by last-quarter revenue ($47.2M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -39.0%, a 19.1% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 67.1%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs 112.3%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
ABCL vs GERN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $47.2M |
| Net Profit | $-8.9M | $-18.4M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | -29.4% |
| Net Margin | -19.9% | -39.0% |
| Revenue YoY | 788.4% | 67.1% |
| Net Profit YoY | 73.9% | 30.3% |
| EPS (diluted) | $-0.03 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | $47.2M | ||
| Q2 25 | $17.1M | $49.0M | ||
| Q1 25 | $4.2M | $39.6M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $6.5M | $28.3M | ||
| Q2 24 | $7.3M | $882.0K | ||
| Q1 24 | $10.0M | $304.0K |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $-18.4M | ||
| Q2 25 | $-34.7M | $-16.4M | ||
| Q1 25 | $-45.6M | $-19.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $-26.4M | ||
| Q2 24 | $-36.9M | $-67.4M | ||
| Q1 24 | $-40.6M | $-55.4M |
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | -29.4% | ||
| Q2 25 | -290.2% | -25.4% | ||
| Q1 25 | -1479.6% | -42.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1439.4% | -99.8% | ||
| Q2 24 | -1276.2% | -7860.9% | ||
| Q1 24 | -551.5% | -18465.1% |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | -39.0% | ||
| Q2 25 | -203.3% | -33.4% | ||
| Q1 25 | -1077.2% | -50.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | -93.5% | ||
| Q2 24 | -504.3% | -7639.8% | ||
| Q1 24 | -408.0% | -18220.4% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | $-0.03 | ||
| Q2 25 | $-0.12 | $-0.02 | ||
| Q1 25 | $-0.15 | $-0.03 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | $-0.04 | ||
| Q2 24 | $-0.13 | $-0.10 | ||
| Q1 24 | $-0.14 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $78.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $248.7M |
| Total Assets | $1.4B | $567.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | $78.1M | ||
| Q2 25 | $92.4M | $77.7M | ||
| Q1 25 | $159.3M | $83.7M | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | $60.3M | ||
| Q2 24 | $148.3M | $116.9M | ||
| Q1 24 | $123.6M | $189.8M |
| Q4 25 | $966.9M | — | ||
| Q3 25 | $964.0M | $248.7M | ||
| Q2 25 | $1.0B | $259.5M | ||
| Q1 25 | $1.0B | $268.2M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | $292.3M | ||
| Q2 24 | $1.1B | $306.7M | ||
| Q1 24 | $1.1B | $344.9M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $567.4M | ||
| Q2 25 | $1.4B | $555.2M | ||
| Q1 25 | $1.3B | $562.5M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | $444.9M | ||
| Q2 24 | $1.4B | $449.4M | ||
| Q1 24 | $1.5B | $482.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-13.6M |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | — | ||
| Q3 25 | $-52.6M | $-13.6M | ||
| Q2 25 | $-32.4M | $-27.4M | ||
| Q1 25 | $-11.6M | $-48.0M | ||
| Q4 24 | $-108.6M | — | ||
| Q3 24 | $-28.9M | $-58.9M | ||
| Q2 24 | $-30.0M | $-53.5M | ||
| Q1 24 | $-41.7M | $-62.3M |
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | $-53.7M | ||
| Q1 24 | $-65.8M | $-62.9M |
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | -6086.6% | ||
| Q1 24 | -661.5% | -20680.3% |
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | 0.0% | ||
| Q2 24 | 274.6% | 23.4% | ||
| Q1 24 | 242.5% | 202.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
